marizomib: Clinical Trials

13 trials of marizomib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 2 terminated, 1 no longer available, 1 withdrawn. 7 Phase 1, 5 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 17Completed 6, Terminated 1
Phase 25Completed 3, Terminated 1, Withdrawn 1
Phase 31Completed 1

Follow marizomib: new trials by email Literature Review of marizomib trials Research Report on marizomib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Marizomib Central Nervous System (CNS)
Marizomib, Pomalidomide, Dexamethasone - Multiple Myeloma, Multiple Myeloma in Relapse
Phase 2WithdrawnDana-Farber Cancer Institute2024-03-012024-07-16
Phase I Study of Marizomib + Panobinostat for Children With DIPG
Marizomib, Panobinostat - Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma
Phase 1TerminatedDana-Farber Cancer Institute42020-08-102024-02-15
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
Marizomib - Anaplastic Ependymoma, Ependymoma
Phase 2TerminatedNational Cancer Institute (NCI)42020-01-222022-07-27
Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab - High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Phase 2CompletedAadi Bioscience, Inc.622018-08-012023-11-07
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
Marizomib, Temozolomide, radiotherapy - Newly Diagnosed Glioblastoma
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC7492018-07-262025-07-01
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
MRZ, TMZ, RT - Glioblastoma, Malignant Glioma
Phase 1CompletedCelgene662016-08-172021-04-19
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
MRZ, BEV - Malignant Glioma, Glioblastoma
Phase 1 / Phase 2CompletedCelgene1212015-04-152022-06-08
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
pomalidomide, marizomib, low-dose dexamethasone - Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Phase 1CompletedCelgene382014-06-052017-11-22
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
NPI-0052 (marizomib) + vorinostat - Non-Small Cell Lung Cancer, Pancreatic Cancer
Phase 1CompletedCelgene222008-03-012017-11-22
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies
NPI-0052 on Days 1, 8, 15 every 28 days, NPI-0052 on Days 1, 4, 8, 11 every 21 days, Dexamethasone - Advanced Cancer
Phase 1CompletedCelgene862007-07-012017-11-22
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
MRZ 0.5 mg/m^2 - Multiple Myeloma
Phase 2CompletedCelgene152007-03-012017-12-19
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
NPI-0052 - Cancer, Lymphomas
Phase 1CompletedCelgene512006-05-012017-11-22
Expanded Access for Marizomib
Marizomib - Solid Tumor
No longer availableCelgene2020-11-25

Conditions studied

Multiple Myeloma (5)  ·  Glioblastoma (3)  ·  Lymphoma (3)  ·  Recurrence (3)  ·  Brain Neoplasms (2)  ·  Glioma (2)  ·  Lymphoma, B-Cell, Marginal Zone (2)  ·  Lymphoma, T-Cell, Cutaneous (2)  ·  Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Diffuse Intrinsic Pontine Glioma (1)  ·  Disease Progression (1)  ·  Ependymoma (1)  ·  Gliosarcoma (1)  ·  Leukemia (1)

Sponsors

Celgene (8)  ·  Dana-Farber Cancer Institute (2)  ·  Aadi Bioscience, Inc. (1)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (11)  ·  Australia (3)  ·  Canada (3)  ·  Switzerland (2)  ·  Austria (1)  ·  Belgium (1)  ·  Denmark (1)  ·  France (1)  ·  Germany (1)  ·  Netherlands (1)  ·  Norway (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Steven D Reich, MD (5)  ·  Clifton Mo, MD (1)  ·  Ileana Elias, M.D. (1)  ·  Ileana Elias, MD (1)  ·  Katherine Warren, MD (1)  ·  Mark R Gilbert, M.D. (1)  ·  Patrick Roth (1)

Results publications

PMID 27009059